porozendoОстеопороз и остеопатииOsteoporosis and Bone Diseases2072-26802311-0716Endocrinology Research Centre10.14341/osteo12944porozendo-12944Research ArticleНаучный обзорReviewГиперпаратиреоз и витамин D: сложности взаимоотношенийHyperparathyroidism and Vitamin D: Relationship Difficultieshttps://orcid.org/0000-0001-9253-8075СуплотоваЛ. А.SuplotovaL. A.

Суплотова Людмила Александровна, д.м.н., профессор 

Тюмень

eLibrary SPIN: 1212-5397

Liudmila A. Suplotova, MD, PhD, Professor

Tyumen

eLibrary SPIN: 1212-5397

suplotovala@mail.ruhttps://orcid.org/0000-0002-8642-9435АвдееваВ. А.AvdeevaV. A.

Авдеева Валерия Александровна, к.м.н.

625023, г. Тюмень, ул. Одесская, д. 54 

eLibrary SPIN: 3215-0880

Valeria A. Avdeeva, MD, PhD

54 Odesskaya street, 625023 Tyumen

eLibrary SPIN: 3215-0880

dr.avdeeva@yahoo.comhttps://orcid.org/0000-0002-1932-1686СудницынаА. С.SudnitsynaA. S.

Судницына Анна Сергеевна

Тюмень

eLibrary SPIN: 2347-6680

Anna S. Sudnitsyna, MD

Tyumen

eLibrary SPIN: 2347-6680

anna0392@inbox.ruhttps://orcid.org/0000-0001-7041-0732РожинскаяЛ. Я.RozhinskayaL. Y.

Рожинская Людмила Яковлевна, д.м.н., профессор

Москва

eLibrary SPIN: 5691-7775

Liudmila Y. Rozhinskaya, MD, PhD, Professor

Moscow

eLibrary SPIN: 5691-7775

lrozhinskaya@gmail.comТюменский государственный медицинский университетРоссияTyumen State Medical UniversityRussian FederationГБУЗ ТО «Областная клиническая больница №1»РоссияGBUZ TO «Regional Clinical Hospital № 1»Russian FederationНациональный медицинский исследовательский центр эндокринологииРоссияEndocrinology Research CentreRussian Federation2022090820222512328Copyright © Суплотова Л.А., Авдеева В.А., Судницына А.С., Рожинская Л.Я., 20222022Суплотова Л.А., Авдеева В.А., Судницына А.С., Рожинская Л.Я.Suplotova L.A., Avdeeva V.A., Sudnitsyna A.S., Rozhinskaya L.Y.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.osteo-endojournals.ru/jour/article/view/12944

Гиперпаратиреоз представляет собой клинико-лабораторный синдром, характеризующийся гиперпродукцией паратиреоидного гормона клетками околощитовидных желез и подразделяющийся в зависимости от причины его возникновения на первичный, вторичный и третичный. К настоящему моменту опубликованы лишь единичные научные труды, посвященные особенностям взаимосвязи витамина D с различными формами гиперпаратиреоза, причин для этого может быть несколько. Во-первых, это связано с тем, что истинная распространенность дефицита витамина D на фоне гиперпаратиреоза неизвестна. Во-вторых, сложности в дифференциальной диагностике гиперпаратиреоза порой влекут за собой не всегда оправданное хирургическое вмешательство с потенциально возможным развитием осложнений, что, безусловно, представляет собой сферу достаточно узкого интереса как в эндокринологии в частности, так и в медицине в целом. В-третьих, бессимптомный, часто скрытый, латентный характер многообразия полиорганных клинических проявлений гиперпаратиреоза в сочетании с низкими уровнями 25(OH)D по мере прогрессирования заболевания может приводить к существенному снижению качества и продолжительности жизни пациентов. Совокупность этих доводов побудила нас обобщить все имеющиеся на сегодняшний день данные о сложностях взаимоотношений между витамином D и различными формами гиперпаратиреоза.

Hyperparathyroidism is a clinical and laboratory syndrome characterized by hyperproduction of parathyroid hormone (PTH) by cells of the parathyroid glands (PTG) and is subdivided, depending on the cause of its occurrence, into primary (PHPT), secondary (SHPT) and tertiary hyperparathyroidism (THPT). To date, only a few scientific papers have been published on the features of the relationship between vitamin D and various forms of hyperparathyroidism, there may be several reasons for this. First, this is due to the fact that the true prevalence of vitamin D deficiency in hyperparathyroidism is unknown. Secondly, difficulties in the differential diagnosis of hyperparathyroidism sometimes entail not always justified surgical intervention with the potential development of complications, which, of course, is a rather narrow area of interest, both in endocrinology in particular and in medicine in general. Thirdly, the asymptomatic, often hidden, latent nature of the variety of multiple organ clinical manifestations of hyperparathyroidism, in combination with low levels of 25(OH)D, as the disease progresses, can lead to a significant decrease in the quality and life expectancy of patients. The combination of these arguments prompted us to summarize all the data available to date on the complexity of the relationship between vitamin D and various forms of hyperparathyroidism.

гиперпаратиреозвитамин D25(OH)Dhyperparathyroidismvitamin D25(OH)DReferencesЗахарова И.Н., Яблочкова С.В., Дмитриева Ю.А. Известные и неизвестные эффекты витамина D. Вопросы современной педиатрии. 2013; 12 (2): 20–25Zakharova IN, Yablochkova SV, Dmitrieva YuA. Well-known and Indeterminate Effects of Vitamin D. Current Pediatrics. 2013;12(2):20-25. (In Russ.). doi: https://doi.org/10.15690/vsp.v12i2.616Duque EJ, Elias RM, Moysés RMA. Parathyroid Hormone: A Uremic Toxin. Toxins (Basel). 2020 Mar 17;12(3):189.Duque EJ, Elias RM, Moysés RMA. Parathyroid Hormone: A Uremic Toxin. Toxins (Basel). 2020;12(3):189. doi: https://doi.org/10.3390/toxins12030189Vélayoudom-Céphise F.-L.,. Wémeau J.-L. Primary hyperparathyroidism and vitamin D deficiency / // Annales d’Endocrinologie. – 2015. – Vol. 76, N 2. – P. 153–162.Vélayoudom-Céphise F-L, Wémeau J-L. Primary hyperparathyroidism and vitamin D deficiency. Ann Endocrinol (Paris). 2015;76(2):153-162. doi: https://doi.org/10.1016/j.ando.2015.03.022Goar St. Case records of Massachusetts general hospital. N Engl J Med. 1963; 268: 943-953Goar St. Case records of Massachusetts general hospital. N Engl J Med. 1963;268:943-953Walker M.D., Bilezikian J.P. Vitamin D and primary hyperparathyroidism: more insights into a complex relationship. Endocrine. 2017 Jan;55(1):3-5. Epub 2016 Nov 17.Walker MD, Bilezikian JP. Vitamin D and primary hyperparathyroidism: more insights into a complex relationship. Endocrine. 2017;55(1):3-5. doi: https://doi.org/10.1007/s12020-016-1169-1Clements M.R., Davies M., Hayes M.E., et al. The role of 1,25-dihydroxyvitamin D in the mechanism of acquired vitamin D deficiency. Clin Endocrinol (Oxf). 1992 Jul;37(1):17-27.Clements MR, Davies M, Hayes ME, et al. The role of 1,25-dihydroxyvitamin D in the mechanism of acquired vitamin D deficiency. Clin Endocrinol (Oxf ). 1992;37(1):17-27. doi: https://doi.org/10.1111/j.1365-2265.1992.tb02278.xBrown A. J. Vitamin D / A. J. Brown, A. Dusso, E. Slatopolsky // Am J Physiol. – 1999. – Vol. 277. – P. F157–E165.Brown AJ, Dusso A, Slatopolsky E. Vitamin D. Am J Physiol Physiol. 1999;277(2):F157-F175. doi: https://doi.org/10.1152/ajprenal.1999.277.2.F157Clements MR, Davies M, Fraser DR, Lumb GA, Mawer EB, Adams PH. Metabolic inactivation of vitamin D is enhanced in primary hyperparathyroidism. Clin Sci (Lond) 1987;73:659–64Clements MR, Davies M, Fraser DR, et al. Metabolic inactivation of vitamin D is enhanced in primary hyperparathyroidism. Clin Sci. 1987;73(6):659-664. doi: https://doi.org/10.1042/cs0730659Yano S., Sugimoto T., Tsukamoto T. et al. Decrease in vitamin D receptor and calcium-sensing receptorin highly proliferative parathyroid adenomas. Eur J Endocrinol. – 2003. – Vol. 148, N 4. – P. 403–411Yano S, Sugimoto T, Tsukamoto T, et al. Decrease in vitamin D receptor and calcium-sensing receptor in highly proliferative parathyroid adenomas. Eur J Endocrinol. 2003;148(4):403-411. doi: https://doi.org/10.1530/eje.0.1480403Moosgaard B., Vestergaard P., Heickendorff L., еt al. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol (Oxf). 2005;63:506–513.Moosgaard B, Vestergaard P, Heickendorff L, et al. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol (Oxf). 2005;63(5):506-513. doi: https://doi.org/10.1111/j.1365-2265.2005.02371.xBoudou P., Ibrahim F., Cormier C., et al. A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism. J Endocrinol Invest. 2006;29:511–515Boudou P, Ibrahim F, Cormier C, et al. A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism. J Endocrinol Invest. 2006;29(6):511-515. doi: https://doi.org/10.1007/BF03344140Rao D.S., Honasoge M., Divine G.W., et al. Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J Clin Endocrinol Metab. 2000;85:1054–1058.Rao DS, Honasoge M, Divine GW, et al. Effect of Vitamin D Nutrition on Parathyroid Adenoma Weight: Pathogenetic and Clinical Implications. J Clin Endocrinol Metab. 2000;85(3):1054-1058. doi: https://doi.org/10.1210/jcem.85.3.6440Moosgaard B, Vestergaard P, Heickendorff L, et al. Plasma 25-hydroxyvitamin D and not 1,25-dihydroxyvitamin D is associated with parathyroid adenoma secretion in primary hyperparathyroidism: a cross-sectional study. Eur J Endocrinol. 2006;155:237–244.Moosgaard B, Vestergaard P, Heickendorff L, et al. Plasma 25-hydroxyvitamin D and not 1,25-dihydroxyvitamin D is associated with parathyroid adenoma secretion in primary hyperparathyroidism: a cross-sectional study. Eur J Endocrinol. 2006;155(2):237-244. doi: https://doi.org/10.1530/eje.1.02197Raef H., Ingemansson S., Sobhi S., et al. The effect of vitamin D status on the severity of bone disease and on the other features of primary hyperparathyroidism (pHPT) in a vitamin D deficient region. J Endocrinol Invest. 2004;27:807–812.Raef H, Ingemansson S, Sobhi S, et al. The effect of vitamin D status on the severity of bone disease and on the other features of primary hyperparathyroidism (pHPT) in a vitamin D deficient region. J Endocrinol Invest. 2004;27(9):807-812. doi: https://doi.org/10.1007/BF03346273Ozbey N., Erbil Y., Ademoglu E., et al. Correlations between vitamin D status and biochemical/clinical and pathological parameters in primary hyperparathyroidism. World J Surg. 2006;30:321–326.Özbey N, Erbil Y, Ademoğlu E, et al. Correlations between Vitamin D Status and Biochemical/Clinical and Pathological Parameters in Primary Hyperparathyroidism. World J Surg. 2006;30(3):321-326. doi: https://doi.org/10.1007/s00268-005-0239-ySilverberg S.J., Shane E., Dempster D.W., et al. The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am J Med. 1999;107:561–567.Silverberg SJ, Shane E, Dempster DW, Bilezikian JP. The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am J Med. 1999;107(6):561-567. doi: https://doi.org/10.1016/S0002-9343(99)00294-6Moosgaard B., Christensen S.E., Vestergaard P., et al. Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism. Clin Endocrinol (Oxf). 2008;68:707–715.Moosgaard B, Christensen SE, Vestergaard P, et al. Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism. Clin Endocrinol (Oxf ). 2008;68(5):707-715. doi: https://doi.org/10.1111/j.1365-2265.2007.03109.xInoue Y, Kaji H, Hisa I, et al. Vitamin D status affects osteopenia in postmenopausal patients with primary hyperparathyroidism. Endocr J. 2008;55:57–65.Inoue Y, Kaji H, Hisa I, et al. Vitamin D Status Affects Osteopenia in Postmenopausal Patients with Primary Hyperparathyroidism. Endocr J. 2008;55(1):57-65. doi: https://doi.org/10.1507/endocrj.K07-102Nordenström E., Westerdahl J., Lindergård B., et al. Multifactorial risk profile for bone fractures in primary hyperparathyroidism. World J Surg. 2002;26:1463–1467.Nordenström E, Westerdahl J, Lindergård B, et al. Multifactorial risk profile for bone fractures in primary hyperparathyroidism. World J Surg. 2002;26(12):1463-1467. doi: https://doi.org/10.1007/s00268-002-6433-2Battista C., Guarnieri V., Carnevale V., еt al. Vitamin D status in primary hyperparathyroidism: effect of genetic background. Endocrine. 2017 Jan;55(1):266-272.Battista C, Guarnieri V, Carnevale V, et al. Vitamin D status in primary hyperparathyroidism: effect of genetic background. Endocrine. 2017;55(1):266-272. doi: https://doi.org/10.1007/s12020-016-0974-xViccica G., Cetani .F, Vignali E., et al. Impact of vitamin D deficiency on the clinical and biochemical phenotype in women with sporadic primary hyperparathyroidism. Endocrine. 2017 Jan;55(1):256-265.Viccica G, Cetani F, Vignali E, et al. Impact of vitamin D deficiency on the clinical and biochemical phenotype in women with sporadic primary hyperparathyroidism. Endocrine. 2017;55(1):256-265. doi: https://doi.org/10.1007/s12020-016-0931-8Walker M.D., Cong E., Lee J.A., Vitamin D in Primary Hyperparathyroidism: Effects on Clinical, Biochemical, and Densitometric Presentation. J Clin Endocrinol Metab. 2015 Sep;100(9):3443-51Walker MD, Cong E, Lee JA, et al. Vitamin D in Primary Hyperparathyroidism: Effects on Clinical, Biochemical, and Densitometric Presentation. J Clin Endocrinol Metab. 2015;100(9):3443-3451. doi: https://doi.org/10.1210/jc.2015-2022Souberbielle, JC, Bienaimé, F, Cavalier, E et al: Vitamin D and primary hyperparathyroidism (PHPT). Ann Endocrinol 2012;73:165–169.Souberbielle J-C, Bienaimé F, Cavalier E, Cormier C. Vitamin D and primary hyperparathyroidism (PHPT). Ann Endocrinol (Paris). 2012;73(3):165-169. doi: https://doi.org/10.1016/j.ando.2012.04.008Walker MD, Fleischer JB, Di Tullio MR, Homma S, Rundek T, Stein EM, Zhang C, Taggart T, McMahon DJ, Silverberg SJ. Cardiac structure and diastolic function in mild primary hyperparathyroidism. J Clin Endocrinol Metab. 2010 May;95(5):2172-9.Walker MD, Fleischer JB, Di Tullio MR, et al. Cardiac Structure and Diastolic Function in Mild Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2010;95(5):2172-2179. doi: https://doi.org/10.1210/jc.2009-2072Торосян М.Р., Киселева Т.П., Чжен Т.Р. Клинико-метаболические нарушения при первичном гиперпаратиреозе. Доктор.Ру. 2020; 19(2): 51–55.Torosyan MR, Kiseleva TP, Chzhen TR. Kliniko-metabolicheskie narusheniya pri pervichnom giperparatireoze. Doktor.Ru. 2020;19(2):51-55. (In Russ.). doi: https://doi.org/10.31550/1727-2378-2020-19-2-51-55Каронова Т.Л., Погосян К.А., Яневская Л. Г., с соавт. Механизмы повреждения сердечно-сосудистой системы при заболеваниях околощитовидных желез. Артериальная гипертензия. 2021;27(1):64–72.Karonova TL, Pogosian KA, Yanevskaya LG, et al. Parathyroid gland disorders and cardiovascular disease. Arterial Hypertension. 2021;27(1):64-72. (In Russ.). doi: https://doi.org/10.18705/1607-419X-2021-27-1-64-72Добрева Е.А., Еремкина А.К., Мирная С.С., с соавт. Кардиоваскулярные нарушения у пациентов с первичным гиперпаратиреозом по данным регистра. Профилактическая медицина. 2020;23(6):Вып. 2:26–35.Dobreva EA, Eremkina AK, Mirnaya SS, et al. Cardiovascular disorders in patients with primary hyperparathyroidism according to registry data. Profilakticheskaya Meditsina. 2020;23(6):26-35. (In Russ.). doi: https://doi.org/10.17116/profmed20202306226Яневская Л.Г., Каронова Т.Л., Слепцов И.В. и соавт Первичный гиперпаратиреоз: клинические формы и их особенности. Результаты ретроспективного исследования. // Клиническая и экспериментальная тиреоидология. – 2019. – Т.15. – №1. – С. 19-29Yanevskaya LG, Karonova TL, Sleptsov IV, et al. Primary hyperparathyroidism: clinical forms and their features. Retrospective study. Clinical and experimental thyroidology. 2019;15(1):19-29. (In Russ.). doi: https://doi.org/10.14341/ket10213Vaidya A, Brown JM, Williams JS. The renin—angiotensin—aldosterone system and calcium-regulatory hormones. Journal of Human Hypertension.2015;29(9):515Vaidya A, Brown JM, Williams JS. The renin–angiotensin–aldosterone system and calcium-regulatory hormones. J Hum Hypertens. 2015;29(9):515-521. doi: https://doi.org/10.1038/jhh.2014.125Brown SJ, Ruppe MD, Tabatabai LS. The parathyroid gland and heart disease. Methodist DeBakey Cardiovascular Journal. 2017;13(2):49.Brown SJ, Ruppe MD, Tabatabai LS. The Parathyroid Gland and Heart Disease. Methodist Debakey Cardiovasc J. 2017;13(2):49. doi: https://doi.org/10.14797/mdcj-13-2-49Randle R.W., Balentine C.J., Wendt E.. Should vitamin D deficiency be corrected before parathyroidectomy? J Surg Res. 2016 Jul;204(1):94-100.Randle RW, Balentine CJ, Wendt E, et al. Should vitamin D deficiency be corrected before parathyroidectomy? J Surg Res. 2016;204(1):94-100. doi: https://doi.org/10.1016/j.jss.2016.04.022Carvalho G.B., Giraldo L.R., Lira R.B., et al. Preoperative vitamin D deficiency is a risk factor for postoperative hypocalcemia in patients undergoing total thyroidectomy: retrospective cohort study. Sao Paulo Med J. 2019 Jul 22;137(3):241-24Carvalho GB de, Giraldo LR, Lira RB, et al. Preoperative vitamin D deficiency is a risk factor for postoperative hypocalcemia in patients undergoing total thyroidectomy: retrospective cohort study. Sao Paulo Med J. 2019;137(3):241-247. doi: https://doi.org/10.1590/1516-3180.2018.0336140319Kaderli, RM, Riss, P, Dunkler, D et al: The impact of Vitamin D status on hungry bone syndrome after surgery for primary hyperparathyroidism. Eur J Endocrinol 2018;178(1):1–9.Kaderli RM, Riss P, Dunkler D, et al. The impact of vitamin D status on hungry bone syndrome after surgery for primary hyperparathyroidism. Eur J Endocrinol. 2018;178(1):1-9. doi: https://doi.org/10.1530/EJE-17-0416Walker, M.D., Fleischer, J.B., Di Tullio, M.R. et al. Cardiac structure and diastolic function in mild primary hyperparathyroidism. Journal of Clinical Endocrinology & Metabolism, 2010, 95, 2172– 2179.Walker MD, Fleischer JB, Di Tullio MR, et al. Cardiac Structure and Diastolic Function in Mild Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2010;95(5):2172-2179. doi: https://doi.org/10.1210/jc.2009-2072Zahrani, A.A. & Levin, M.A. Primary hyperparathyroidism. Lancet 1997., 349, 1233– 1238.Zahrani AA, Levin MA. Primary hyperparathyroidism. Lancet. 1997;349:1233-1238.Tucci, J.R. Vitamin D therapy in patients with primary hyperparathyroidism and hypovitaminosis D. European Journal of Endocrinology, 2009, 161, 189– 193.Tucci JR. Vitamin D therapy in patients with primary hyperparathyroidism and hypovitaminosis D. Eur J Endocrinol. 2009;161(1):189-193. doi: https://doi.org/10.1530/EJE-08-0901Jithpratuck, W., Garrett, L.H. & Peiris, A.N. Treating vitamin D insufficiency in primary hyperparathyroidism: a cautionary tale. Tennessee Medicine, 2011, 104, 47– 49.Jithpratuck W, Garrett LH, Peiris AN. Treating vitamin D insufficiency in primary hyperparathyroidism: a cautionary tale. Tenn Med. 2011;104:47-49.Song A, Zhao H, Yang Y, et al. Safety and efficacy of common vitamin D supplementation in primary hyperparathyroidism and coexistent vitamin D deficiency and insufficiency: a systematic review and meta-analysis. J Endocrinol Invest. 2021 Aug;44(8):1667-1677.Song A, Zhao H, Yang Y, et al. Safety and efficacy of common vitamin D supplementation in primary hyperparathyroidism and coexistent vitamin D deficiency and insufficiency: a systematic review and meta-analysis. J Endocrinol Invest. 2021;44(8):1667-1677. doi: https://doi.org/10.1007/s40618-020-01473-5Rolighed L., Rejnmark L., Sikjaer T., еt al. Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial. J Clin Endocrinol Metab. 2014 Mar;99(3):1072-80Rolighed L, Rejnmark L, Sikjaer T, et al. Vitamin D Treatment in Primary Hyperparathyroidism: A Randomized Placebo Controlled Trial. J Clin Endocrinol Metab. 2014;99(3):1072-1080. doi: https://doi.org/10.1210/jc.2013-3978Shah, V.N., Shah, C.S., Bhadada, S.K. et al. Effect of 25 (OH) D replacements in patients with primary hyperparathyroidism (PHPT) and coexistent vitamin D deficiency on serum 25(OH) D, calcium and PTH levels: A meta-analysis and review of literature. Clin. Endocrinol. (Oxf). 2014; 80:797–803.Shah VN, Shah CS, Bhadada SK, Rao DS. Effect of 25 (OH) D replacements in patients with primary hyperparathyroidism (PHPT) and coexistent vitamin D deficiency on serum 25(OH) D, calcium and PTH levels: a meta-analysis and review of literature. Clin Endocrinol (Oxf ). 2014;80(6):797-803. doi: https://doi.org/10.1111/cen.12398Ross AC, Manson JE, Abrams SA. et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011;96:53-58Ross AC, Manson JE, Abrams SA, et al. The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know. J Clin Endocrinol Metab. 2011;96(1):53-58. doi: https://doi.org/10.1210/jc.2010-2704Heaney R.P., Holick M.F. Why the IOM recommendations for vitamin D are deficient. j Bone Miner Res 2011;26:455-457.Heaney RP, Holick MF. Why the IOM recommendations for vitamin D are deficient. J Bone Miner Res. 2011;26(3):455-457. doi: https://doi.org/10.1002/jbmr.328Chandran M, Hoeck H.C., Wong H.C., et al. Vitamin D status and its relationship with bone mineral density and parathryoid hormone in Southeast Asian adults with low bone density. Endocr Pract 2011;17:226-234Chandran M, Hoeck HC, Wong HC, et al. Vitamin d status and its relationship with bone mineral density and parathyroid hormone in southeast asian adults with low bone density. Endocr Pract. 2011;17(2):226-234. doi: https://doi.org/10.4158/EP10202.ORSong A, Zhao H, Yang Y et al. Safety and efficacy of common vitamin D supplementaiton in primary hyperparathyroidism and coexistent vitamin D deficiency and insufficiency: a systematic review and meta-analysis. J Endocinolog Inveset 2021;Jan 16th on line ahead of print.Song A, Zhao H, Yang Y, et al. Safety and efficacy of common vitamin D supplementation in primary hyperparathyroidism and coexistent vitamin D deficiency and insufficiency: a systematic review and meta-analysis. J Endocrinol Invest. 2021;44(8):1667-1677. doi: https://doi.org/10.1007/s40618-020-01473-5Loh H.H., Lim L.L., Yee A., et al. Effect of vitamin D replacement in primary hyperparathyroidism with concurrent vitamin D deficiency: a systematic review and meta-analysis. Minerva Endocrinol. 2019 Jun;44(2):221-231Loh HH, Lim LL, Yee A, Loh HS, Vethakkan SR. Effect of vitamin D replacement in primary hyperparathyroidism with concurrent vitamin D deficiency: a systematic review and meta-analysis. Minerva Endocrinol. 2019;44(2):221-231. doi: https://doi.org/10.23736/S0391-1977.17.02584-6Walker M.D., Bilezikian JP. Vitamin D and primary hyperparathyroidism: more insights into a complex relationship. Endocrine 2017;55:3-5Walker MD, Bilezikian JP. Vitamin D and primary hyperparathyroidism: more insights into a complex relationship. Endocrine. 2017;55(1):3-5. doi: https://doi.org/10.1007/s12020-016-1169-1Егшатян Л.В., Мокрышева Н.Г., Рожинская Л.Я. Вторичный и третичный гиперпаратиреоз при хронической болезни почек // Остеопороз и остеопатии. — 2017. — Т. 20. — №2. — С.63-68Egshatyan LV, Mokrisheva NG, Rozhinskaya LY. Secondary and tertiary hyperparathyroidism in chronic kidney disease. Osteoporosis and Bone Diseases. 2017;20(2):63-68. (In Russ.). doi: https://doi.org/10.14341/osteo2017263-68Минерально-костный обмен при хронической болезни почек / Н.Г. Мокрышева, Л.В. Егшатян. — Москва : ООО «Медицинское информационное агентство», 2020. — 424 с.: илMokrysheva NG, Egshatyan LV. Mineral’no-kostnyi obmen pri khronicheskoi bolezni pochek. Moscow: OOO «Meditsinskoe informatsionnoe agentstvo»; 2020. 424 p. (In Russ.).Мокрышева Н.Г., Еремкина А.К., Мирная С.С., и соавт. Трудности дифференциальной диагностики между первичной и вторичной формами гиперпаратиреоза // Ожирение и метаболизм. — 2017. — Т.14. — №. 3 — С.48-53.Mokrysheva NG, Eremkina AK, Mirnaya SS, et al. Challenges in differential diagnosis between primary and secondary forms of hyperparathyroidism. Obesity and metabolism. 2017;14(3):48-53. (In Russ.). doi: https://doi.org/10.14341/omet2017348-53McDermott M. Endocrine Secrets. 4-е издание, исправ. И дополн. / Пер. с анго. М.: Издательский дом БИНОМ, 2017. - 584 с.McDermott M. Endocrine Secrets. 4-е издание, исправ. и дополн., пер. с анг. М.: Издательский дом БИНОМ; 2017. 584 с. [McDermott M. Endocrine Secrets. 4-e izdanie. Moscow: Izdatel’skii dom BINOM; 2017. 584 p. (In Russ.)].Bouillon R. Comparative analysis of nutritional guidelines for vitamin D. Nat Rev Endocrinol 2017; 13: 466–479Bouillon R. Comparative analysis of nutritional guidelines for vitamin D. Nat Rev Endocrinol. 2017;13(8):466-479. doi: https://doi.org/10.1038/nrendo.2017.31Binkley N, Dawson Hughes B, Durazo Arvizu R, et al Vitamin D measurement standardization: the way out of the chaos. J Steroid Biochem Mol Biol 2017; 173: 117–121.Binkley N, Dawson-Hughes B, Durazo-Arvizu R, et al. Vitamin D measurement standardization: The way out of the chaos. J Steroid Biochem Mol Biol. 2017;173:117-121. doi: https://doi.org/10.1016/j.jsbmb.2016.12.002Heijboer AC, Blankenstein MA, Kema IP, et al. Accuracy of 6 routine 25‐hydroxyvitamin D assays: influence of vitamin D binding protein concentration. Clin Chem 2012; 58: 543–548Heijboer AC, Blankenstein MA, Kema IP, Buijs MM. Accuracy of 6 Routine 25-Hydroxyvitamin D Assays: Influence of Vitamin D Binding Protein Concentration. Clin Chem. 2012;58(3):543-548. doi: https://doi.org/10.1373/clinchem.2011.176545Manson JE, Brannon PM, Rosen CJ, Taylor CL. Vitamin D deficiency – is there really a pandemic? N Engl J Med 2016; 375: 1817–1820Manson JE, Brannon PM, Rosen CJ, Taylor CL. Vitamin D Deficiency — Is There Really a Pandemic? N Engl J Med. 2016;375:1817-1820. doi: https://doi.org/10.1056/nejmp1608005Krall EA, Sahyoun N, Tannenbaum S et al. Effect of vitamin D intake on seasonal variations in parathyroid hormone secretion in postmenopausal women. Engl J Med. 1989;321:1777–1783.Krall EA, Sahyoun N, Tannenbaum S, et al. Effect of Vitamin D Intake on Seasonal Variations in Parathyroid Hormone Secretion in Postmenopausal Women. N Engl J Med. 1989;321(26):1777-1783. doi: https://doi.org/10.1056/NEJM198912283212602Lips P, Wiersinga A, van Ginkel FC, et al. The effect of vitamin D supplementation on vitamin D status and parathyroid function in elderly subjects. J Clin Endocrinol Metab. 1988;67:644–650.Lips P, Wiersinga A, Van Ginkel FC, et al. The Effect of Vitamin D Supplementation on Vitamin D Status and Parathyroid Function in Elderly Subjects. J Clin Endocrinol Metab. 1988;67(4):644-650. doi: https://doi.org/10.1210/jcem-67-4-644Sai AJ, Walters RW, Fang X, et al. Relationship between vitamin D, parathyroid hormone, and bone health.. J Clin Endocrinol Metab. 2011;96:436–446.Sai AJ, Walters RW, Fang X, Gallagher JC. Relationship between Vitamin D, Parathyroid Hormone, and Bone Health. J Clin Endocrinol Metab. 2011;96(3):E436-E446. doi: https://doi.org/10.1210/jc.2010-1886Aloia JF, Talwar SA, Pollack S, et al. Am Optimal vitamin D status and serum parathyroid hormone concentrations in African American women. J Clin Nutr. 2006;84:602–609.Aloia JF, Talwar SA, Pollack S, et al. Optimal vitamin D status and serum parathyroid hormone concentrations in African American women. Am J Clin Nutr. 2006;84(3):602-609. doi: https://doi.org/10.1093/ajcn/84.3.602Ginde AA, Wolfe P, Camargo CA Jr, et al. Defining vitamin D status by secondary hyperparathyroidism in the US population. J Endocrinol Invest. 2012;35:42–48.Ginde AA, Wolfe P, Camargo CA, Schwartz RS. Defining vitamin D status by secondary hyperparathyroidism in the U.S. population. J Endocrinol Invest. 2012;35:42-48. doi: https://doi.org/10.3275/7742Monk RD, Bushinsky DA.Making sense of the latest advice on vitamin D therapy. J Am Soc Nephrol. 2011;22:994–998Monk RD, Bushinsky DA. Making Sense of the Latest Advice on Vitamin D Therapy. J Am Soc Nephrol. 2011;22(6):994-998. doi: https://doi.org/10.1681/ASN.2011030251Olmos JM, Hernández JL, García-Velasco P, et al. Serum 25-hydroxyvitamin D, parathyroid hormone, calcium intake, and bone mineral density in Spanish adults. Osteoporos Int. 2016;27:105-113.Olmos JM, Hernández JL, García-Velasco P, et al. Serum 25-hydroxyvitamin D, parathyroid hormone, calcium intake, and bone mineral density in Spanish adults. Osteoporos Int. 2016;27(1):105-113. doi: https://doi.org/10.1007/s00198-015-3219-6Shen M, Li Z, Lv D, et al. Seasonal variation and correlation analysis of vitamin D and parathyroid hormone in Hangzhou, Southeast China. J Cell Mol Med. 2020 Jul;24(13):7370-7377.Shen M, Li Z, Lv D, et al. Seasonal variation and correlation analysis of vitamin D and parathyroid hormone in Hangzhou, Southeast China. J Cell Mol Med. 2020;24(13):7370-7377. doi: https://doi.org/10.1111/jcmm.15330Zhang Q, Shi L, Peng N, et al. Serum concentrations of 25‐hydroxyvitamin D and its association with bone mineral density and serum parathyroid hormone levels during winter in urban males from Guiyang, Southwest China. Br J Nutr. 2016;115:960‐966.Zhang Q, Shi L, Peng N, et al. Serum concentrations of 25-hydroxyvitamin D and its association with bone mineral density and serum parathyroid hormone levels during winter in urban males from Guiyang, Southwest China. Br J Nutr. 2016;115(6):960-966. doi: https://doi.org/10.1017/S0007114515005383AlQuaiz AM, Mujammami M, Kazi A, et al. Vitamin D cutoff point in relation to parathyroid hormone: a population based study in Riyadh city, Saudi Arabia. Arch Osteoporos. 2019;14(1):22. doi: https://doi.org/10.1007/s11657-019-0565-6AlQuaiz AM, Mujammami M, Kazi A, et al. Vitamin D cutoff point in relation to parathyroid hormone: a population based study in Riyadh city, Saudi Arabia. Arch Osteoporos. 2019;14(1):22. doi: https://doi.org/10.1007/s11657-019-0565-6Берсенев Г.А., Ильичёва Е.А., Булгатов Д.А. Спорные вопросы этиологии и патогенеза третичного гиперпаратиреоза. Acta biomedica scientifica. 2019; 4(5): 104-115Bersenev GA, Ilyicheva EA, Bulgatov DA. Disputable Issues of Etiology and Pathogenesis of Tertiary Hyperparathyroidism. Acta Biomedica Scientifica. 2019;4(5):104-115. (In Russ.). doi: https://doi.org/10.29413/ABS.2019-4.5.17

The authors declare that there are no conflicts of interest present.